These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 11169964)

  • 1. Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice.
    Heukamp LC; van der Burg SH; Drijfhout JW; Melief CJ; Taylor-Papadimitriou J; Offringa R
    Int J Cancer; 2001 Feb; 91(3):385-92. PubMed ID: 11169964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
    Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
    Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
    Pietersz GA; Li W; Osinski C; Apostolopoulos V; McKenzie IF
    Vaccine; 2000 Apr; 18(19):2059-71. PubMed ID: 10706970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
    Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
    Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cytotoxic T cell response to peptide analogs of the HLA-A*0201-restricted MUC1 signal sequence epitope, M1.2.
    Mitchell MS; Lund TA; Sewell AK; Marincola FM; Paul E; Schroder K; Wilson DB; Kan-Mitchell J
    Cancer Immunol Immunother; 2007 Mar; 56(3):287-301. PubMed ID: 16874487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.
    Brossart P; Heinrich KS; Stuhler G; Behnke L; Reichardt VL; Stevanovic S; Muhm A; Rammensee HG; Kanz L; Brugger W
    Blood; 1999 Jun; 93(12):4309-17. PubMed ID: 10361129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans.
    Geluk A; van Meijgaarden KE; Franken KL; Drijfhout JW; D'Souza S; Necker A; Huygen K; Ottenhoff TH
    J Immunol; 2000 Dec; 165(11):6463-71. PubMed ID: 11086086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.
    Tsang KY; Palena C; Gulley J; Arlen P; Schlom J
    Clin Cancer Res; 2004 Mar; 10(6):2139-49. PubMed ID: 15041735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.
    Street MD; Doan T; Herd KA; Tindle RW
    Immunology; 2002 Aug; 106(4):526-36. PubMed ID: 12153516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
    Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
    J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Derivation of HLA-B*0702 transgenic mice: functional CTL repertoire and recognition of human B*0702-restricted CTL epitopes.
    Alexander J; Oseroff C; Sidney J; Sette A
    Hum Immunol; 2003 Feb; 64(2):211-23. PubMed ID: 12559623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
    Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
    Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.
    Stepensky D; Tzehoval E; Vadai E; Eisenbach L
    Clin Exp Immunol; 2006 Jan; 143(1):139-49. PubMed ID: 16367945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.
    Jochems C; Tucker JA; Vergati M; Boyerinas B; Gulley JL; Schlom J; Tsang KY
    Cancer Immunol Immunother; 2014 Feb; 63(2):161-74. PubMed ID: 24233342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An altered HLA-A0201-restricted MUC1 epitope that could induce more efficient anti-tumor effects against gastric cancer.
    Yu H; Ye C; Li J; Pan C; Lin W; Chen H; Zhou Z; Ye Y
    Exp Cell Res; 2020 May; 390(1):111953. PubMed ID: 32156601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
    Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
    Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immunization of A2/K(b) transgenic mice with the KMP11-HSP70 fusion protein induces CTL response against human cells expressing the T. cruzi KMP11 antigen: identification of A2-restricted epitopes.
    Marañón C; Thomas MC; Planelles L; López MC
    Mol Immunol; 2001 Aug; 38(4):279-87. PubMed ID: 11566321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
    Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
    Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.
    Butterfield LH; Meng WS; Koh A; Vollmer CM; Ribas A; Dissette VB; Faull K; Glaspy JA; McBride WH; Economou JS
    J Immunol; 2001 Apr; 166(8):5300-8. PubMed ID: 11290817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myeloma.
    Kang YJ; Zeng W; Song W; Reinhold B; Choi J; Brusic V; Yamashita T; Munshi A; Li C; Minvielle S; Anderson KC; Munshi N; Reinherz EL; Sasada T
    Br J Haematol; 2013 Nov; 163(3):343-51. PubMed ID: 24032635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.